Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW YORK–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.


To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13744589. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MR conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.

Establishment Labs’ Motiva silicone gel-filled implants are currently not approved for commercial distribution in the United States. The Company’s implants are undergoing PMA clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.

Contacts

Investor/Media Contact:
Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Staff

Recent Posts

Healing Realty Trust Appoints Healthcare Staffing Veteran Matt Young to Board of Directors

Jupiter, Florida--(Newsfile Corp. - June 11, 2025) - Healing Realty Trust, a data-driven, self-managed real…

1 hour ago

YOUR SKIN BARRIER NEEDS YOU: BYOMA LAUNCHES SECOND ANNUAL SKIN BARRIER AWARENESS MONTH

BYOMA, the trailblazing brand investing millions to improve worldwide skin barrier health, announces the second…

1 hour ago

South Dakota Office of Licensing and Accreditation (OLA) Implements New MIS from RedMane Technology

CHICAGO, June 11, 2025 /PRNewswire/ -- South Dakota Office of Licensing and Accreditation (OLA) recently…

1 hour ago

Zorro Secures $20 Million in Series A to Transform the Healthcare Benefits Industry for Brokers, Employers and Employees

First-of-its-Kind Insurtech Bridges Gap between Health and Financial Wellbeing, Offering a Benefits Solution that Delivers…

1 hour ago